March 04, 2026

GIMEMA ALL2820: Chemotherapy-Free Regimen Studied in Front-Line Setting

As front-line therapy, a chemotherapy-free regimen combining the tyrosine kinase inhibitor (TKI) ponatinib and the bispecific T-cell engager blinatumomab significantly outperformed standard treatment ...

The ASCO Post

March 03, 2026

Miami Cancer Institute Leads Landmark Phase 2 Glioblastoma Trial

The randomized Phase 2 CRUX-2 trial (Ruxolitinib in Combination with Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma) is currently recruiting.

Baptist Health South Florida

March 03, 2026

Kyaw Aung, M.B.B.S., Ph.D., Joins Baptist Health Miami Cancer Institute

Medical oncologist Kyaw Aung, M.B.B.S., Ph.D., has joined Baptist Health Miami Cancer Institute. He specializes in gastrointestinal cancers, particularly pancreatic cancer.

Baptist Health South Florida

February 27, 2026

Sequencing Therapies in Non-Hodgkin Lymphomas

Guiding oncology practitioners on integrating advanced therapies for B-cell non-Hodgkin lymphomas, JADPRO Live 2025 featured critical insights from F. Brianne Buchanan and Tatjana Grgic.

JADPRO

February 27, 2026

Boca Raton Regional Hospital Foundation Honors Donors at Proton Therapy Center

The Boca Raton Regional Hospital Foundation celebrated with donors the upcoming addition of proton therapy at the Eugene M. & Christine E. Lynn Cancer Institute, at the Harvey & Phyllis Sandler Pavilion at Boca Raton Regional Hospital, part of Baptist Health.  

Baptist Health South Florida

February 27, 2026

Latest Clinical Evidence in Extensive-Stage Small Cell Lung Cancer Treatment

Discover the latest strategies in the treatment and management of extensive-stage small cell lung cancer, emphasizing the critical role of supportive care and advancements in therapy. - JADPRO Live.

JADPRO

February 27, 2026

Novel Therapies and Multidisciplinary Strategies in Metastatic Triple-Positive Breast Cancer

Explore the latest insights on treating metastatic triple-positive breast cancer, emphasizing multimodal therapy and adverse event management, as discussed by oncology experts at JADPRO Live 2025.

JADPRO

February 27, 2026

2024–2025 Drug Updates in Solid Tumors

Explore the latest in solid tumor therapies that prioritize patient quality of life, presented by Dr. Kevin Y. Chen at JADPRO Live 2025.

JADPRO

February 27, 2026

United in Care at JADPRO Live 2025

JADPRO Live 2023 showcased groundbreaking collaborations in oncology education and practice, uniting healthcare professionals to enhance cancer care.

JADPRO

February 25, 2026

Can Induction Improve Survival in High-Risk, Locally Advanced Cervical Cancer?

Rates of overall and progression-free survival for locally advanced cervical cancer have risen significantly since 2024, when the FDA approved the use of pembrolizumab (brand name Keytruda) with chemoradiation for stage 3-4A disease.

Roswell Park Comprehensive Cancer Center